Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL3035093 | 0.93 | TAS2R14 (0.54) | NFE2L2KEAP1FFAR4PGRENPP2 | |
| SCHEMBL14120564 | 0.89 | PTGES2 (0.52) | NFE2L2KEAP1FFAR4PGRCA12 | |
| SCHEMBL14572638 | 0.88 | PGR (0.58) | NFE2L2KEAP1PGRENPP2TAS2R14 | |
| SCHEMBL31352975 | 0.83 | MTNR1B (0.56) | NFE2L2KEAP1FFAR4PGRCA12 | |
| SCHEMBL3151230 | 0.83 | MTNR1B (0.56) | NFE2L2KEAP1FFAR4PGRCA12 | |
| 1,3-Dimethoxybenzene SCHEMBL2179669 | 0.83 | ACHE (0.54) | NFE2L2PGRCA12CA1CA2 | |
| SCHEMBL11155550 | 0.82 | NFE2L2 (0.54) | NFE2L2KEAP1FFAR4PGRCA12 | |
| Anisole SCHEMBL22187427 | 0.82 | ALDH1A1 (0.67) | PGRTAS2R14GAA | |
| SCHEMBL803706 | 0.82 | NFE2L2 (0.54) | NFE2L2KEAP1FFAR4PGRCA12 | |
| SCHEMBL29650302 | 0.82 | NFE2L2 (0.54) | NFE2L2KEAP1FFAR4PGRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925606-B | 5- (3- (sulfonamide) phenyl) -1H-pyrrole-2-carboxylic acid derivative and preparation method and application thereof | 宁夏医科大学 | 2023-10-13 | — | — | CN | claimed |
| CN-115193419-B | Magnetic microsphere, preparation method, application and diagnostic kit thereof | 苏州纳微生命科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-115193419-A | Magnetic microsphere, preparation method, application and diagnostic kit thereof | 苏州纳微生命科技有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | claimed |
| EP-2385831-A2 | SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT | The UAB Research Foundation (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110254866-A1 | INFORMATION PROCESSING APPARATUS, METHOD AND PROGRAM THEREFORE | SONY CORPORATION (JP) | 2011-10-20 | — | — | US | claimed |
| WO-2010123591-A2 | SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT | THE UAB RESEARCH FOUNDATION (US) | 2010-10-28 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010862-A | Novel PET tracer agent targeting cannabinoid type 2 receptor and preparation method thereof | 杭州吉蕊科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-4443477-A | ANTICOAGULANTS, ANTILIPEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-04-17 | — | — | US | disclosed |
| EP-0038458-B1 | 4-HYDROXY-1,2-BENZISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE, THEIR SALTS, THEIR PREPARATION AND THEIR UTILIZATION | Dr. Karl Thomae GmbH (DE) | 1983-09-21 | — | — | EP | disclosed |
| US-4404230-A | ARTICIFIAL SWEETENERS | DR. KARL THOMAE GMBH (DE) | 1983-09-13 | — | — | US | disclosed |
| EP-0038458-A1 | 4-Hydroxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide, their salts, their preparation and their utilization | Dr. Karl Thomae GmbH (DE) | 1981-10-28 | — | — | EP | disclosed |
| US-4131680-A | Hypotensive sulphonamidopiperidyl indoles | JOHN WYETH & BROTHER LTD. (GB) | 1978-12-26 | — | — | US | disclosed |
| US-3947471-A | CHROMOGENIC | SUMITOMO CHEMICAL COMPANY, LTD. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | NFE2L2 1608/4885KEAP1 2197/4885FFAR4 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.